Health Canada has authorized the first generic semaglutide injection indicated for weight loss.
The drug, called Svemia, was submitted by Canadian-based Apotex and is a generic version of the brand-name drug Wegovy.
Health Canada says the authorization followed a review of evidence from the company showing the drug meets federal safety, efficacy and quality standards for generic drugs.
Once-weekly treatment approved
The semaglutide injection is approved as a once-weekly treatment for patients 12 and older for chronic weight management.
Health Canada says it is intended to be used along with a reduced-calorie diet and increased physical activity.
The department says generic semaglutide products are complex synthetic products that are pharmaceutically equivalent to the brand-name biologic drug.
Its review is meant to ensure any differences between the products do not affect safety, effectiveness or quality.
Related Stories:
More submissions under review
Health Canada says it is currently reviewing six other submissions for generic semaglutide from different companies.
The department says more regulatory decisions are expected in the coming weeks and months.
This is the third generic semaglutide product approved by Health Canada overall. Earlier this year, Apotex received approval for a generic semaglutide injection used once weekly to manage blood sugar levels in adults with Type 2 diabetes.
Health Canada says generic drugs can help create potential cost savings for patients and the health-care system.
The department says it will continue monitoring the safety and effectiveness of all generic semaglutide products authorized in Canada.